Vanderbilt University: Triple-Negative Breast Cancer Drug Therapy Shows Promise
March 14, 2020
March 14, 2020
NASHVILLE, Tennessee, March 14 [TNSmedicalresearch] -- Vanderbilt University issued the following news:
Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
MYCN is a well-known oncogene that plays a role in cancer aggressiveness, but it is typically associated with neuronal and . . .
Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
MYCN is a well-known oncogene that plays a role in cancer aggressiveness, but it is typically associated with neuronal and . . .